Tel Aviv, Israel
Tel Aviv, Israel

Tel Aviv University is a public university located in Ramat Aviv, Tel Aviv, Israel. With over 30,000 students, TAU is Israel's largest university.Located in Israel's cultural, financial and technological core, Tel Aviv University is a major center of teaching and research, comprising 9 faculties, 27 schools, 98 departments and nearly 130 research institutes and centers. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Patent
Tel Aviv University | Date: 2017-04-05

A transistor (100), including a planar semiconducting substrate (36), a source (42) formed on the substrate, a first drain (102) formed on the substrate, and a second drain (104) formed on the substrate in a location physically separated from the first drain. At least one gate (38, 40) is formed on the substrate and is configured to selectably apply an electrical potential to the substrate in either a first spatial pattern, which causes a first conductive path (62) to be established within the substrate from the source to the first drain, or a second spatial pattern, which causes a second conductive path to be established within the substrate from the source to the second drain.


Patent
Tel Aviv University | Date: 2017-02-08

An optical element is disclosed. The optical element comprises: a first phase shift mask formed on a first optical material and constituted to generate a positive phase shift, and a second phase shift mask formed on a second optical material and constituted to generate a negative phase shift, wherein the phase shift masks are arranged serially on an optical axis, and wherein a refractive index of at least one of the first and second optical materials varies with the temperature at a rate of at least 5010^(6 )per degree Kelvin.


A method of generating a particle is disclosed, the particle being for delivery of a polynucleotide to a target cell. The method comprises (a) contacting the polynucleotide with a composition comprising cationic molecules, wherein the cationic molecules condense the polynucleotide by electrostatic interactions to generate a complex, wherein the cationic molecules are not comprised in a liposome; and (b) covalently binding the complex to a targeting moiety at a pH equal to or below about 4.5, thereby generating the particle for delivery of the polynucleotide agent to the target cell. Use of the particles and compositions comprising same are also disclosed.


Apparatus and method for efficiently assessing the results of reflectance spectroscopy on a soil sample to determine the presence of contaminants in the soil, by constructing a model based on analysis of known samples. The model may be constructed using an all possibilities approach and data mining techniques, on a range of samples, for example of different kinds of soil without pollutants and with different levels of pollutants. The Disclosure relates both to the construction of the model and to its use in the field in analyzing soil contaminants.


A method of treating or preventing gonadal or uterine toxicity induced by an agent in a subject is provided. Accordingly there is provided a method comprising administering to a subject a therapeutically effective amount of pigment epithelium- derived factor (PEDF), thereby treating or preventing the gonadal toxicity induced by the agent. Also provided is, a method comprising determining gonadal function in a subject; and administering to the subject a therapeutically effective amount of PEDF, thereby treating or preventing the gonadal toxicity induced by the agent. Also provided is a PEDF for use in the treatment or prevention of gonadal toxicity induced by an agent in a subject. Also provided are cell culture, a medium, a kit and method for improving oocyte quality ex-vivo.


Patent
Tel Aviv University | Date: 2017-01-25

There is provided a method for matching subject data to database patient data based on matching phenotypes and related genetic sequences, comprising: receiving a dataset including at least one phenotype disease description of a subject and a genetic sequence of the subject, the phenotype disease description describing clinically significant manifestations of disease in the subject; calculating a ranking score for each of a dataset of patients, the ranking score indicative of a similarity correlation between the dataset of each respective patient and the dataset of the subject, wherein the related genetic sequences of the dataset of patients are underlying genetic mutations attributable to the at least one phenotypic disease description; matching the dataset of the subject with at least one dataset of patients according to a requirement of the ranking score; and providing data indicative of the matched patients.


Patent
Tel Aviv University | Date: 2017-01-12

An isolated peptide comprising a Huntingtin (Htt) amino acid sequence being no longer than 15 amino acids, wherein said Htt amino acid sequence comprises the sequence X_(1)X_(2)X_(3)X_(4 )X_(5), wherein X_(1 )is a hydrophobic amino acid or threonine, X_(2 )is a hydrophobic amino acid, X_(3 )is a hydrophobic amino acid, X_(4 )is an acidic amino acid and X_(5 )is selected from the group consisting of glycine, serine and alanine, the peptide capable of specifically inhibiting the activity of caspase 6.


Patent
Tel Aviv University | Date: 2017-01-06

A conductive nanowire film having a high aspect-ratio metal is described. The nanowire film is produced by inducing metal reduction in a concentrated surfactant solution containing metal precursor ions, a surfactant and a reducing agent. The metal nanostructures demonstrate utility in a great variety of applications.


Patent
Tel Aviv University | Date: 2017-05-03

There are provided liposomes, comprising cationic lipids, a membrane stabilizing lipid and at least one lipid conjugated to a polyethylene glycol (PEG) derivative, in particular PEG-amine, the liposomes are coated with a glycosaminoglycan, in particular, Hyaluronic Acid (HA), compositions comprising the same, methods for their preparation and uses thereof for the efficient delivery of nucleic acids, such as, si RNA molecules and for treating various conditions, such as cancer.


Isolated mortalin peptides and antibodies are provided. Accordingly there is provided an isolated peptide comprising no more than 30 amino acids having a mortalin amino acid sequence and being capable of killing cancer cells and/or enhancing complement activity; also provided is an antibody comprising an antigen recognition domain having an amino acid sequence which binds mortalin and enhances complement- dependent cytotoxicity (CDC). Also provided are compositions and methods for inhibiting mortalin activity, killing a cell and treating a disease associated with a pathological cell population.

Loading Tel Aviv University collaborators
Loading Tel Aviv University collaborators